Skip to main content
. 2024 May 5;12(5):500. doi: 10.3390/vaccines12050500

Figure A8.

Figure A8

Vaccine efficacy (VE) for respiratory syncytial virus (RSV) vaccines in older adults (age ≥ 70/75 years) with lower respiratory tract disease (LRTD) with 2 signs/symptoms (I2 0.0%, 95% CI 0.0 to 89.6; tau2 0.0, 95% CI 0.0 to 29.114; Q = 1.79, p = 0.409) [51,52,82].